Cannabis sativa as a possible treatment for alleviating both motor and nonmotor symptoms of Parkinson’s disease: A meta-analysis
Clicks: 2
ID: 284751
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.3
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #1,339 of 3,757 articles by views in Malay Journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 3,757 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder and has a significant impact on the quality of life as it constitutes a wide-ranging complication. There is no known cure other than medications for the management of symptoms. The growing interest in using cannabis-derived medications has led to an increased demand for therapeutic evidence of Cannabis sativa for the potential to counteract oxidative cell damage and neuroinflammation. Therefore, the purpose of the study is to determine the treatment effect of the intervention and add to the existing knowledge on the effect of medical cannabis on both motor and non-motor symptoms of Parkinson’s Disease by conducting a comprehensive meta-analysis. The literature search was conducted using five (5) online databases and in compliance with PRISMA-2020 guidelines and protocol. Randomized controlled trials (RCTs) assessing the effect of medical cannabis on the symptoms of Parkinson’s Disease were eligible. The literature was assessed for bias using Cochrane’s Risk of Bias Tool. The analysis was performed with the total Unified Parkinson’s Disease Rating Scale (UPDRS) as the primary outcome and subscale scores as secondary outcomes. Data were analyzed using the Cochrane Collaboration's RevMan 5.4, where the standardized mean difference was estimated with a 95% confidence interval. In addition, heterogeneity was tested through Cochran’s Q-statistic, I-squared, and tau-squared values. Three (3) RCTs involving 88 PD patients were eligible for the analysis; all are defined with a low risk of bias. Although the findings of this study showed that the use of cannabis-based medications might benefit in alleviating the motor and nonmotor symptoms of patients with Parkinson’s Disease based on the primary outcome (pooled SMD: -0.18, 95% CI −0.68 to 0.32; p = 0.48), there is still insufficient evidence to support its therapeutic potential. Given the limited nature of the available literature, further investigation is needed for future studies.
| Reference Key |
persistent_1760653577_68f17109e452a
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Pacaña, Arcadia Marie Q. |
| Journal | Malay Journal |
| Year | 2023 |
| DOI |
DOI not found
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.